Brandy Dawson Cumberland
Psychiatric/Mental Health · Salisbury, MDNPI 1497410633
Payments from drug & device makers
Across 13 payments — averaging $16.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$65
- Teva Pharmaceuticals USA, Inc.$32
- Boehringer Ingelheim$21
- Exact Sciences$19
- Supernus Pharmaceuticals, Inc.$16
- Neurocrine Biosciences, Inc.$16
- plus $39 from 3 others
What the payments were for
- Food & beverage$208100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 4 | $65 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
| Boehringer Ingelheim | 1 | $21 |
| Exact Sciences | 1 | $19 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
| Neurocrine Biosciences, Inc. | 1 | $16 |
| Bayer | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $12 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
How this compares
$208 in reported general payments places this provider in the 35th percentile of 1,461 psychiatric/mental health providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 12 | $41,613 |
| VraylarCariprazine Hcl | 11 | $16,000 |
| Lurasidone Hcl | 47 | $15,969 |
| Atomoxetine Hcl | 20 | $1,068 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 28 | $895 |
| Quetiapine Fumarate | 74 | $768 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 29 | $542 |
| Aripiprazole | 19 | $513 |
| Doxepin Hcl | 11 | $431 |
| Trazodone Hcl | 32 | $302 |
| Hydroxyzine Pamoate | 24 | $277 |
| Risperidone | 33 | $255 |
| Buspirone Hcl | 32 | $253 |
| Sertraline Hcl | 38 | $243 |
| Lithium Carbonate | 16 | $232 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Salisbury
- Hara OyedejiOwings Mills$780K
- Ilya RozenbergGlen Burnie$572K
- Michelle WilliamsColumbia$158K
- Kristin ClemensGaithersburg$36K
- Antonio HeroldHavre de Grace$23K
- Paul KlaverweidenFruitland$17K
- Margaret WebbAberdeen$16K
- Susan KrausTowson$16K
- Anyinke AtabongRockville$15K
- Zenatsehay GebretsadikColumbia$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.